News coverage about AxoGen (NASDAQ:AXGN) has trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. AxoGen earned a news sentiment score of 0.23 on Accern’s scale. Accern also assigned news stories about the medical equipment provider an impact score of 45.8994032817565 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern Sentiment’s rankings:
- Why Technical Analysis Matters on AxoGen, Inc. (AXGN) – Wall Street Morning (wallstreetmorning.com)
- AxoGen, Inc. (AXGN) stock crosses SMA-20 above 17.05% – The Stocks News (press release) (thestocksnews.com)
- AxoGen, Inc. (AXGN) – Lookout Technical Picture – Wall Street Morning (wallstreetmorning.com)
- AxoGen, Inc. (AXGN) moves 29.12% above SMA-50 – The Stocks News (press release) (thestocksnews.com)
- Jefferies Group Increases AxoGen (AXGN) Price Target to $45.00 (americanbankingnews.com)
AxoGen stock opened at $39.40 on Thursday. The company has a current ratio of 4.07, a quick ratio of 3.53 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $1,305.71, a PE ratio of -131.33 and a beta of 0.10. AxoGen has a fifty-two week low of $9.95 and a fifty-two week high of $39.60.
Several brokerages have issued reports on AXGN. Jefferies Group increased their price target on AxoGen to $45.00 and gave the stock a “buy” rating in a report on Monday. Lake Street Capital set a $38.00 price target on AxoGen and gave the stock a “buy” rating in a report on Friday, March 2nd. JMP Securities increased their price target on AxoGen from $27.00 to $34.00 and gave the stock a “market outperform” rating in a report on Thursday, March 1st. BidaskClub upgraded AxoGen from a “buy” rating to a “strong-buy” rating in a report on Friday, February 23rd. Finally, William Blair initiated coverage on AxoGen in a report on Monday, February 5th. They set an “outperform” rating for the company. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $33.14.
In other AxoGen news, Director Jamie Mark Grooms sold 63,395 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $27.67, for a total value of $1,754,139.65. Following the completion of the transaction, the director now directly owns 5,827 shares in the company, valued at $161,233.09. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders sold 169,407 shares of company stock valued at $4,593,013. Corporate insiders own 9.33% of the company’s stock.
TRADEMARK VIOLATION WARNING: “AxoGen (AXGN) Receives News Impact Score of 0.23” was published by BBNS and is the property of of BBNS. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://baseballnewssource.com/2018/03/22/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-axogen-axgn-share-price/1972456.html.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.